Journal September 26, 2026 5 min read

Which peptides are studied in relation to exosomes?

A research-catalogue summary of peptides and proteins investigated alongside exosomes, spanning podocyte markers, LL-37, FGF21, Cerebrolysin, and others. All findings are from laboratory or clinical studies and are not i

peptides-pro Editorial

The peptides and proteins most frequently studied in relation to exosomes include podocyte-specific proteins (nephrin, podocalyxin, Wilms' tumor protein WT-1), the antimicrobial peptide LL-37, fibroblast growth factor 21 (FGF21), and the neurotrophic peptide preparation Cerebrolysin. These are investigated as exosomal cargo, as modifiers of exosome release, or as components of exosome-based therapeutic strategies. Identifiers such as sequence, formula, and molecular weight are not provided in the evidence block for these compounds.

The work centres on pathways including EGFR signaling, AMPK/mTOR, and TGF-β/SMAD, as well as on exosome-mediated intercellular communication in kidney, skin, and neural tissues.

Research Studies

Podocyte-specific proteins and exosomes in diabetic kidney disease

A clinical study is examining podocyte-specific proteins (PSP) — nephrin, podocalyxin, and WT-1 — in urinary exosomes from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD) [1]. The study compares empagliflozin, finerenone, or combination therapy. Secondary objectives include correlating exosome-based PSP with standard kidney injury biomarkers (urine albumin/creatinine ratio and estimated GFR) and with systemic inflammatory markers such as interleukins (IL-1, IL-6, IL-12) and hs-CRP [1]. This is an ongoing clinical study; no results are reported in the evidence block.

LL-37 and melanoma exosomes

In melanoma, exosomal hsa-miR-221-5p was found to suppress keratinocyte expression of the antimicrobial peptide LL-37 through impaired sustained EGFR signaling [2]. Functionally, keratinocyte-derived LL-37 curtailed melanoma cell migration, invasion, and epithelial-mesenchymal transition, restrained tumor growth in vivo, and was associated with a tumor immune microenvironment enriched in M1 macrophages [2]. The findings are from laboratory and animal models.

FGF21-modified exosomes and wound healing

Fibroblast growth factor 21 (FGF21)-modified adipose-derived mesenchymal stem cell (ADSC) exosomes were studied for their effect on wound healing [3]. The exosomes, termed Exo@FGF21, were isolated and characterized, and the study aimed to elucidate mechanisms by which they promote wound healing, including activation of fibroblast glycolysis through AMPK/mTOR signaling [3]. This work is preclinical.

Cerebrolysin-treated endothelial cell exosomes and permeability

Exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) were tested in an in vitro endothelial permeability assay [4]. Cerebro-Exos showed marked differences in cargo profiles compared to exosomes from untreated cells (Naïve-Exos), being highly enriched with metabolic and tight junction-related proteins. Cerebro-Exos had a superior effect on restoring endothelial cell integrity impaired by fibrin and tissue plasminogen activator (tPA) [4]. This is an in vitro study.

Glutathione and umbilical cord blood-derived exosomes in autism spectrum disorder

A 12-month clinical study is testing whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3–12 [5]. Approximately 100 children with confirmed autism are randomized to receive either monthly intravenous AdiaVita plus intravenous glutathione for 3 months, or intravenous glutathione plus a saline placebo infusion for 2 months; both groups also use a topical glutathione spray twice daily at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC) [5]. This is an ongoing clinical study; no results are reported.

Neuronal exosomes and exercise biomarkers

A clinical study is examining the brain-based biological mechanistic pathway by which exercise exerts anxiolytic effects [7]. The investigators measure brain-derived markers of mitochondrial metabolism (acetyl-L-carnitine) and inflammation (interleukin-6) using technology to isolate neuronal exosomes [7]. This is an ongoing study; no results are reported.

Wharton's jelly exosomes and liver cirrhosis

A clinical study is using autologous bone marrow-derived mononuclear cells combined with Wharton's jelly exosomes (20 billion per dose) to stimulate hepatic cell repair in patients with liver cirrhosis [8]. The protocol involves harvesting bone marrow-derived mononuclear cells, concentrating and testing viability, then combining with a small volume (2 cc) of Wharton's jelly exosomes for intravenous administration [8]. This is an ongoing study; no results are reported.

Other peptides and exosome-related mechanisms

Additional studies have explored peptides in exosome contexts. Cancer-associated fibroblast-derived exosomes delivering Snail were investigated for promoting pancreatic cancer stemness and gemcitabine resistance via the SOCS6/HIF-1α axis [9]. Mesenchymal stem cell-derived exosomes loaded in chitosan hydrogel were studied in a full-thickness porcine skin defect model [10]. Combinatorial therapy of LL-37 and adipose-derived stem cells was examined in diabetic wound repair, focusing on NRROS-mediated crosstalk between TGF-β/SMAD and Hippo/TEAD1 axes [11]. Surface-engineered GE11-functionalized exosomes were used for EGFR-targeted peonidin delivery and suppression of SNAI1-mediated epithelial-mesenchymal transition in glioma [12]. These are preclinical findings.

If you are reading this for personal health reasons

The compounds and materials described here are sold for laboratory research only. We do not provide dosing, medical guidance, or recommendations for human use. Anyone considering a compound for themselves should speak to a licensed clinician.